The CHIC Symposium on HPV for Southeast Asia and the Pacific gathered 95 delegates from 17 countries in Manila to exchange strategies, challenges, and successes in vaccination programs. Discussions emphasized cultural understanding, political advocacy, and the shift toward single-dose regimens to improve coverage and sustainability. Delegates highlighted collaborative approaches for securing vaccine supply chains, addressing […]
Symposium ID: Manila2024
Feedback of Day 1 – Participants
The session opened with reflections on lessons learned from the previous day, emphasizing multi-sectoral collaboration, community engagement, schools as vaccination hubs, tailored communication, catch-up campaigns, data monitoring, and flexible strategies for out-of-school populations. Participants from the Philippines, Malaysia, Timor-Leste, Pakistan, and others highlighted insights relevant to their national contexts, including leveraging volunteers for outreach, addressing […]
Welcome Notes
The fourth CHIC Regional Symposium on HPV for Southeast Asia and the Western Pacific took place in Manila, hosted by the Philippine Department of Health in collaboration with the University of Antwerp, the London School of Hygiene and Tropical Medicine, and JHPIEGO. Gathering 95 participants from 17 countries, the event aimed to strengthen HPV vaccination […]
Country Snapshots – Day 1 Overview
Invited countries participated in the country snapshot gallery session, which served as an icebreaker to ensure that all stakeholders in the room understood the respective HPV vaccination programs of the countries in attendance before diving into specific challenges and solutions.
Feedback of Day 1 &2 – Participants
The third day opened with reflections on key learnings from previous sessions, emphasizing practical insights gained from peer exchanges. Malaysia’s experience highlighted the value of volunteers in vaccination programs and the shift toward digital data systems that integrate vaccination with HPV testing. Participants underscored the importance of strong communication when transitioning from multi-dose to single-dose […]
Concluding Remarks
The closing session celebrated three days of rich exchange among 95 participants from 17 countries, highlighting shared challenges and innovative solutions for HPV vaccination. Key themes included multisectoral collaboration, sustainability through financing transitions, robust data systems, and innovative approaches such as single-dose schedules and outreach to out-of-school girls. Organizers and partners—including the Department of Health […]
Single-dose scientific evidence data and implementation progress
The session reviewed global evidence underpinning the WHO’s 2022 recommendation for single-dose HPV vaccination. Data from pivotal trials in Costa Rica, India, and Kenya demonstrated sustained efficacy exceeding 80–90% against HPV 16/18 infection for over a decade. Immunogenicity studies confirmed durable antibody responses comparable to multi-dose schedules, with similar outcomes in boys and girls. Population-level […]
Considerations for HPV Vaccine product choice
The WHO presentation reviewed the global status of HPV vaccine introduction, noting that 74% of countries have adopted HPV vaccination programs with increasing coverage driven by major introductions in Asia and Africa. It highlighted the 2022 recommendation for a single-dose schedule, now adopted by 58 countries, including high-income nations. Recent evidence supports the inclusion of […]
Accelerated Gavi transitioning experience and HPV vaccine procurement experience
Lao PDR is undergoing a phased transition from Gavi-supported vaccine financing toward full self-financing by 2025, with projected co-financing obligations steadily increasing. HPV vaccination, introduced in 2020 and procured through UNICEF, targets 10-year-old girls with a single-dose schedule, requiring fewer than 100,000 doses annually at an estimated cost of USD 500,000. The country has consistently […]
HPV vaccine cost and procurement – transitioning out of Gavi support and self-procurement
The Indonesian experience in HPV vaccine procurement highlights the transition from Gavi support to full self-financing within the national immunization program. Facing high cervical cancer incidence, the country initiated phased rollouts since 2016, progressing to nationwide coverage in 2022. Post-Gavi strategies include technology transfer to Biofarma for local vaccine production and cost reduction. Key challenges […]